RGNX 241115 10.00P (RGNX241115P10000) Stock Options, News & Quotes

US OptionsDetailed Quotes

RGNX241115P10000

Watchlist

0.40
-0.95-70.37%

15min DelayClose Nov 7 16:00 ET

0.40High0.40Low

Intraday

5D
Daily

News

Regenxbio Analyst Ratings
Benzinga15:32 ET · Ratings
Stifel Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $40
Moomoo NewsNov 7 10:34 ET · Ratings
H.C. Wainwright Maintains Regenxbio(RGNX.US) With Buy Rating, Raises Target Price to $40
Moomoo NewsNov 7 07:31 ET · Ratings
RBC Capital Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $35
Moomoo NewsNov 7 07:31 ET · Ratings
RegenXBio's Promising Gene Therapy Advancements and Strategic Financial Growth: A Buy Recommendation
TipRanksNov 7 06:36 ET · Ratings
Express News | Regenxbio Inc. : H.c. Wainwright Raises Target Price to $40 From $39
ReutersNov 7 06:15 ET

Comments

Stock_Drift

Oct 21 06:09

$Regenxbio (RGNX.US)$

Stock_Drift

Sep 23 15:16

$Regenxbio (RGNX.US)$

Bingrru

Aug 1 09:20

$Regenxbio (RGNX.US)$

Tao Lao Zoa

Mar 5 11:19

$Regenxbio (RGNX.US)$ SELL SELL SELL NOW EASY MONEY AND ENJOIN YOURS TAKE BREAK TOMORROW 💰💰💰😋😋😋🤩🤩🤩

Moomoo AI

Feb 17 07:06

Investors' pessimism about the company's revenue prospects may be causing the low P/S ratio. The company's forecast growth is lower than the wider industry, which could be contributing to the depressed P/S. It's hard to see the share price rising strongly in the near future given these circumstances.

There's No Escaping REGENXBIO Inc.'s (NASDAQ:RGNX) Muted Revenues Despite A 33% Share Price Rise